Apoptosis

Apoptosis is an autonomous, genetically controlled, orderly death of cells to maintain the stability of the internal environment. Unlike necrosis, apoptosis is not a passive process, but an active one, involving the activation, expression and regulation of a series of genes, and it is not a phenomenon of autologous damage under pathological conditions, but an active death process for better adaptation to the survival environment. Apoptosis is a fundamental biological phenomenon of cells and plays a necessary role in the removal of unwanted or abnormal cells in multicellular organisms. It plays an important role in the evolution of organisms, the stability of the internal environment, and the development of several systems. Apoptosis is not only a specific type of cell death, but also has important biological significance and complex molecular biological mechanisms.

Cat. No.	Product name
BP10962	Saikosaponin C
BP10962	Saikosaponin C efficiently inhibited LPS-induced apoptotic cell death via inhibition of caspase-3 activation and caspase-3-mediated-FAK degradation.
BP10183	Sal003
BP10183	Sal003, an effective cell-permeable analog, inhibitis the eIF2α phosphatase.
BP10133	Salermide
BP10133	Salermide is an inhibitor of Sirt1 and Sirt2, causing strong cancer-specific apoptotic cell death.
BP10055	Salidroside
BP10055	Salidroside is a bioactive phenolic glycoside compound isolated from Rhodiola crenulata. It is a prolyl endopeptidase Inhibitor.
BP10659	Salvianolic acid F
BP10659	The role of our hybrid molecules, an analogue of Salvianolic acid F, in compelling the glioma cells towards apoptosis by specifically perturbing the concentration of glutathione along with caspase 6.
BP10805	Samuraciclib hydrochloride
BP10805	Samuraciclib hydrochloride is a potent, selective, ATP competitive and oral active CDK7 inhibitor with IC50 of 41 nM. The selectivity of Samuraciclib hydrochloride is 45-, 15-, 230- and 30-fold higher than CDK1, CDK2 (IC50 is 578 nM), CDK5 and CDK9 respectively. Samuraciclib hydrochloride inhibits the growth of breast cancer cell lines with GI50 values between 0.2-0.3 μM. Samuraciclib hydrochloride has anti-tumor effects.
BP10142	SAR125844
BP10142	SAR125844, a potent and highly selective inhibitor of the MET receptor tyrosine kinase (RTK), for intravenous administration. (IC50 value of 4.2 nmol/L)
BP10533	SAR131675
BP10533	SAR 131675 is a potent and selective VEGFR3 inhibitor with an IC50 of 23 nM.
BP10558	SAR-20347
BP10558	SAR-20347 is an inhibitor of TYK2, JAK1/2/3 (IC50: 0.6/23/26/41 nM).
BP10351	SAR405838
BP10351	MI-773 (SAR405838) is an orally available MDM2 antagonist with Ki of 0.88 nM. Phase 1.
BP10319	Sarsasapogenin
BP10319	Sarsasapogenin is a steroidal sapogenin, that is the aglycosidic portion of a plant saponin. It is named after sarsaparilla (Smilax sp.), a family of climbing plants found in subtropical regions. It was one of the first sapogenins to be identified, and the first spirostan steroid to be identified as such.
BP10613	SB 202190
BP10613	SB 202190 is a selective and cell-permeable inhibitor of p38 MAPK (IC50s: 50/100 nM for p38α/p38β).
BP10229	SB1317
BP10229	SB1317 is a potent inhibitor of cyclin dependant kinases (CDKs), Janus kinase 2 (JAK2), and Fms-like tyrosine kinase-3 (FLT3).
BP10084	SBE13 Hydrochloride
BP10084	SBE13 hydrochloride is an effective and specific PLK1 inhibitor (IC50: 0.2 nM); no inhibition om Aurora A kinase, Plk2/3.
BP10860	SBI-0206965
BP10860	SBI-0206965 is a potent, selective and cell-permeable autophagy kinase ULK1 inhibitor with IC50 of 108 nM for ULK1 kinase activity and 711 nM for ULK2.
BP10820	SBI-0640756
BP10820	SBI-0640756 (SBI-756) is a first-in-class inhibitor that targets eIF4G1 and disrupts the eIF4F complex.
BP10746	SC-236
BP10746	Sc 236 is an orally active and selective inhibitor of COX-2 (IC50 of 0.005 μM and 17.8 μM for COX-2 and COX-1, respectively).
BP10469	SC-43
BP10469	SC-43 is a potent and orally active agonist of SHP-1 (PTPN6). SC-43 inhibits the phosphorylation of STAT3 and induces cell apoptosis, and with anti-fibrotic and anticancer effects.
BP10241	SCH79797 dihydrochloride
BP10241	SCH79797 dihydrochloride is an effective and selective antagonist of protease activated receptor 1 (PAR1) with an IC50 of 70 nM and a Ki of 35 nM. SCH79797 dihydrochloride has antiproliferative and pro-apoptotic effects.
BP10192	SCR-1481B1
BP10192	SCR-1481B1 has activity against cancers dependent on Met activation and also has activity against cancers as a VEGFR inhibitor